SI2604695T1 - Replikacijsko defektni arenavirusni vektorji - Google Patents

Replikacijsko defektni arenavirusni vektorji

Info

Publication number
SI2604695T1
SI2604695T1 SI200832203T SI200832203T SI2604695T1 SI 2604695 T1 SI2604695 T1 SI 2604695T1 SI 200832203 T SI200832203 T SI 200832203T SI 200832203 T SI200832203 T SI 200832203T SI 2604695 T1 SI2604695 T1 SI 2604695T1
Authority
SI
Slovenia
Prior art keywords
replication
arenavirus vectors
defective arenavirus
defective
vectors
Prior art date
Application number
SI200832203T
Other languages
English (en)
Slovenian (sl)
Inventor
Daniel David Pinschewer
Lukas Roland Flatz
Andreas Bergthaler
Rudolf M. Zinkernagel
Original Assignee
Universitaet Zuerich Prorektorat Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Zuerich Prorektorat Forschung filed Critical Universitaet Zuerich Prorektorat Forschung
Publication of SI2604695T1 publication Critical patent/SI2604695T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
SI200832203T 2007-12-27 2008-12-22 Replikacijsko defektni arenavirusni vektorji SI2604695T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07025099 2007-12-27
EP13152727.7A EP2604695B1 (en) 2007-12-27 2008-12-22 Replication-defective arenavirus vectors

Publications (1)

Publication Number Publication Date
SI2604695T1 true SI2604695T1 (sl) 2023-03-31

Family

ID=40428182

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200832203T SI2604695T1 (sl) 2007-12-27 2008-12-22 Replikacijsko defektni arenavirusni vektorji

Country Status (15)

Country Link
US (7) US8592205B2 (enExample)
EP (3) EP4186978A1 (enExample)
JP (3) JP5642556B2 (enExample)
CN (3) CN101918565B (enExample)
CA (1) CA2744910C (enExample)
DK (2) DK2238255T3 (enExample)
ES (2) ES2937147T3 (enExample)
FI (1) FI2604695T3 (enExample)
HR (1) HRP20221475T3 (enExample)
HU (1) HUE061060T2 (enExample)
LT (1) LT2604695T (enExample)
PL (2) PL2238255T3 (enExample)
PT (1) PT2604695T (enExample)
SI (1) SI2604695T1 (enExample)
WO (1) WO2009083210A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186978A1 (en) * 2007-12-27 2023-05-31 Universität Zürich Replication-defective arenavirus vectors
WO2011034953A2 (en) * 2009-09-16 2011-03-24 The Administrators Of The Tulane Educational Fund Lassa virus-like particles and methods of production thereof
CA2836977A1 (en) * 2010-06-06 2011-12-15 Benjamin R. Tenoever Recombinant rna viruses and uses thereof
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
ES2758713T3 (es) * 2011-07-11 2020-05-06 Inovio Pharmaceuticals Inc Vacuna de ADN contra el virus de Lassa
SMT202400297T1 (it) 2013-03-13 2024-09-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Proteine f del rsv pre-fusione e loro uso
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
HRP20211015T1 (hr) 2013-12-03 2021-10-01 Hookipa Biotech Gmbh Cjepivo protiv citomegalovirusa (cmv)
WO2015123592A2 (en) 2014-02-13 2015-08-20 Synthetic Genomics, Inc. Recombinant rna particles and methods of use
JP6673838B2 (ja) 2014-02-14 2020-04-01 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
AU2015321557B2 (en) 2014-09-22 2020-05-14 Regents Of The University Of Minnesota Pichinde virus reverse genetics system and methods of use
US10722564B2 (en) * 2014-11-13 2020-07-28 Université de Genéve Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CN107921117B (zh) * 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
WO2018045029A1 (en) * 2016-09-02 2018-03-08 The United States Of America, As Represented By The Secretary Of The Army Pan south american arenavirus live attenuated vaccine
US11214598B2 (en) * 2015-11-04 2022-01-04 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
EP3960197A1 (en) * 2015-11-12 2022-03-02 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
US11260090B2 (en) * 2016-03-08 2022-03-01 University Of Vermont And State Agricultural College Modified arenavirus
CN117486979A (zh) * 2016-05-18 2024-02-02 巴塞尔大学 作为疫苗载体的三区段pichinde病毒
CA3039356A1 (en) 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
CN110719788A (zh) 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
WO2020255023A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
EP4458975A3 (en) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US20220362361A1 (en) * 2019-10-18 2022-11-17 University Of Virginia Patent Foundation Compositions and methods for producing enhanced immune responses and rapid antibody production
EP4055173A1 (en) * 2019-11-07 2022-09-14 Universität Basel Vizerektorat Forschung Arenaviruses as vectors
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
BR112023019365A2 (pt) 2021-03-23 2023-12-26 Hookipa Biotech Gmbh Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit
WO2022238546A1 (en) 2021-05-13 2022-11-17 Hookipa Biotech Gmbh Arenaviruses as vectors
EP4429698A1 (en) 2021-11-08 2024-09-18 Hookipa Biotech GmbH Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
CN117343911A (zh) * 2022-06-28 2024-01-05 中国科学院上海药物研究所 一种缺陷型丝状病毒的制备方法及其应用
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US7267823B2 (en) 1998-06-29 2007-09-11 United States Of America As Represented By The Secretary Of The Army Ebola peptides and immunogenic compositions containing same
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
AU2002331572A1 (en) 2002-04-17 2003-11-03 Astropower, Inc. Maximum power sensor for photovoltaic system
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
WO2005061534A2 (en) 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
US20070005929A1 (en) * 2005-06-30 2007-01-04 Post Daniel J Method, system, and article of manufacture for sector mapping in a flash device
EP4186978A1 (en) 2007-12-27 2023-05-31 Universität Zürich Replication-defective arenavirus vectors
AU2012204757A1 (en) 2011-01-07 2013-05-02 Bioscience Slovakia Viral diagnostics
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
HRP20211015T1 (hr) 2013-12-03 2021-10-01 Hookipa Biotech Gmbh Cjepivo protiv citomegalovirusa (cmv)
US10722564B2 (en) 2014-11-13 2020-07-28 Université de Genéve Tri-segmented arenaviruses as vaccine vectors
CN107921117B (zh) 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
US11214598B2 (en) 2015-11-04 2022-01-04 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
EP3960197A1 (en) 2015-11-12 2022-03-02 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
CN117486979A (zh) 2016-05-18 2024-02-02 巴塞尔大学 作为疫苗载体的三区段pichinde病毒
CA3039356A1 (en) 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
CN110719788A (zh) 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
EP4055173A1 (en) 2019-11-07 2022-09-14 Universität Basel Vizerektorat Forschung Arenaviruses as vectors
EP4157342A1 (en) 2020-05-29 2023-04-05 Hookipa Biotech GmbH Cancer treatment strategies using arenavirus vectors
BR112023019365A2 (pt) 2021-03-23 2023-12-26 Hookipa Biotech Gmbh Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit

Also Published As

Publication number Publication date
US9944952B2 (en) 2018-04-17
WO2009083210A1 (en) 2009-07-09
LT2604695T (lt) 2022-12-12
EP2604695A1 (en) 2013-06-19
US10655145B2 (en) 2020-05-19
US20160194663A1 (en) 2016-07-07
HK1151829A1 (zh) 2012-02-10
US20220315951A1 (en) 2022-10-06
ES2438773T3 (es) 2014-01-20
FI2604695T3 (fi) 2023-02-16
US20100297172A1 (en) 2010-11-25
EP2604695B1 (en) 2022-11-16
PL2604695T3 (pl) 2023-04-11
US8592205B2 (en) 2013-11-26
CA2744910C (en) 2018-01-30
CN103993012B (zh) 2023-01-10
ES2937147T3 (es) 2023-03-24
US20140050760A1 (en) 2014-02-20
EP2238255B1 (en) 2013-09-11
CN101918565A (zh) 2010-12-15
CN103993012A (zh) 2014-08-20
EP2238255A1 (en) 2010-10-13
CA2744910A1 (en) 2009-07-09
DK2238255T3 (da) 2013-11-18
US9309289B2 (en) 2016-04-12
HUE061060T2 (hu) 2023-05-28
US20210071198A1 (en) 2021-03-11
EP4186978A1 (en) 2023-05-31
US20190062784A1 (en) 2019-02-28
JP2011507536A (ja) 2011-03-10
JP2014239688A (ja) 2014-12-25
JP2017079738A (ja) 2017-05-18
JP6227094B2 (ja) 2017-11-08
US20250369015A1 (en) 2025-12-04
CN101918565B (zh) 2014-04-30
PT2604695T (pt) 2022-12-07
JP5642556B2 (ja) 2014-12-17
DK2604695T3 (da) 2023-01-16
CN103255169A (zh) 2013-08-21
US11401528B2 (en) 2022-08-02
HRP20221475T3 (hr) 2023-01-06
PL2238255T3 (pl) 2014-02-28
US12227755B2 (en) 2025-02-18

Similar Documents

Publication Publication Date Title
HUE061060T2 (hu) Replikáció-defektív arenavírus vektorok
EP2222861A4 (en) Polypurine tract modified retroviral vectors
LU92600I2 (fr) Sovaldi (sofosbuvir)
KR101608166B9 (ko) 펌프 카세트
DK2205737T3 (da) Mikromirer
EP2185560A4 (en) HETEROARYLAMIDE ANALOGS
DK2159224T3 (da) Bromphenylsubstituerede thiazolyldihydropyrimidiner
BRPI0807137A2 (pt) Agentes antiparasitários
FI20075873A0 (fi) Suotokuristinjärjestely
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
EP2211752A4 (en) biopulp
DK2146570T3 (da) Herbicidsammensætning
FI20075277A0 (fi) Radiaalisiipipyörä
EP2216932A4 (en) BITS IDENTIFICATION CIRCUIT
BRPI0816450A2 (pt) Fungicidas
EP2195521A4 (en) Fuel vapor separator
DK2221298T3 (da) Phenylpyrazolderivater
DE112008003196A5 (de) Handpipettiergerät
DE602008006131D1 (de) Schussfadeneintragdüse
FI20075250A0 (fi) Ruokintalaitteisto
FI20075057A0 (fi) Mäntähydraulimoottori
EP2171383A4 (en) STRIPPER AIR BLADE STABILIZER
EP2128006A4 (en) DRIVING TYPE VEHICLE IN CALIFOURCHON
DK2155715T3 (da) ((Phenyl)imidazolyl)methylheteroarylforbindelser
FIU20070172U0 (fi) Välpepesuri